Our study provides a potential target for the prevention and treatment of GC patients, and targeting the METTL3-m6A-YTHDC1-FAM120A-SLC7A11 pathway is expected to improve cisplatin resistance of GC patients. Here, YTHDC1 is linked to gastric cancer.